
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Mol. Cancer</journal-id><journal-title-group><journal-title>Molecular Cancer</journal-title></journal-title-group><issn pub-type="epub">1476-4598</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25744782</article-id><article-id pub-id-type="pmc">4342943</article-id><article-id pub-id-type="publisher-id">314</article-id><article-id pub-id-type="doi">10.1186/s12943-015-0314-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>The long non-coding RNA <italic>PCGEM1</italic> is regulated by androgen receptor activity <italic>in vivo</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Parolia</surname><given-names>Abhijit</given-names></name><address><email>aparolia@bccrc.ca</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Crea</surname><given-names>Francesco</given-names></name><address><email>fcrea@bccrc.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Xue</surname><given-names>Hui</given-names></name><address><email>hxue@bccrc.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Yuwei</given-names></name><address><email>yuwang@bccrc.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Mo</surname><given-names>Fan</given-names></name><address><email>fmo@prostatecentre.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Ramnarine</surname><given-names>Varune Rohan</given-names></name><address><email>vramnarine@prostatecentre.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Hui Hsuan</given-names></name><address><email>rliu@bccrc.ca</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Dong</given-names></name><address><email>dlin@bccrc.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Saidy</surname><given-names>Nur Ridzwan Nur</given-names></name><address><email>rnursaidy@bccrc.ca</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Clermont</surname><given-names>Pier-Luc</given-names></name><address><email>pclermont@bccrc.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Hongwei</given-names></name><address><email>hcheng@bccrc.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Collins</surname><given-names>Colin</given-names></name><address><email>ccollins@prostatecentre.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Wang</surname><given-names>Yuzhuo</given-names></name><address><email>ywang@bccrc.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Helgason</surname><given-names>Cheryl D</given-names></name><address><email>chelgaso@bccrc.ca</email></address><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff6"/></contrib><aff id="Aff1"><label/>Honours Biotechnology Program, Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC Canada </aff><aff id="Aff2"><label/>Experimental Therapeutics, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3 Canada </aff><aff id="Aff3"><label/>The Vancouver Prostate Centre, Vancouver General Hospital, Vancouver, BC Canada </aff><aff id="Aff4"><label/>Interdisciplinary Oncology Program, Faculty of Medicine, University of British Columbia, Vancouver, BC Canada </aff><aff id="Aff5"><label/>Department of Urologic Sciences, University of British Columbia, Vancouver, BC Canada </aff><aff id="Aff6"><label/>Department of Surgery, University of British Columbia, Vancouver, BC Canada </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>14</volume><elocation-id>46</elocation-id><history><date date-type="received"><day>18</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>5</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Parolia et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Long non-coding RNAs (lncRNAs) can orchestrate oncogenic or tumor-suppressive functions in cancer biology. Accordingly, <italic>PCGEM1</italic> and <italic>PRNCR1</italic> were implicated in progression of prostate cancer (PCa) as transcriptional co-regulators of the androgen receptor (AR). However, these findings were recently refuted asserting that neither gene physically binds to the AR. Despite evidence for differing AR transcriptional programs <italic>in vivo</italic> and <italic>in vitro</italic>, studies investigating AR-regulation of these genes hitherto have only been conducted <italic>in vitro</italic>. Here, we further examine the relevance of <italic>PCGEM1</italic> and <italic>PRNCR1</italic> in PCa, and their relationship with AR signaling, using patient-derived xenograft models.</p></sec><sec><title>Findings</title><p>RNA sequencing of two distinct androgen-dependent models shows <italic>PCGEM1</italic> to be considerably expressed, while <italic>PRNCR1</italic> showed scant basal expression. <italic>PCGEM1</italic> was sharply down-regulated following castration and up-regulated upon AR activation <italic>in vivo</italic>. However, we found no parallel evidence following AR stimulation <italic>in vitro</italic>. A <italic>PCGEM1</italic>-associated gene expression signature (PES) was significantly repressed in response to androgen ablation therapy and in hormone-refractory versus hormone-na&#x000ef;ve PCa patients. Furthermore, we found <italic>PCGEM1</italic> was uniformly distributed in PCa cell nucleus and cytoplasm which remained unaltered upon AR transcriptional activation. <italic>PCGEM1</italic> was up-regulated in primary PCa but not in metastasized PCa. Accordingly, the PES was significantly down-regulated in advanced and higher grade PCa patients from multiple independent studies.</p></sec><sec><title>Conclusion</title><p>Our results demonstrate <italic>PCGEM1</italic> as an <italic>in vivo</italic> androgen-regulated transcript with potential nuclear and/or cytoplasmic function(s). Importantly, the clinical expression profile of <italic>PCGEM1</italic> implicates it in the early stages of PCa warranting further research in this direction.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12943-015-0314-4) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Long non-coding RNAs</kwd><kwd>lncRNAs</kwd><kwd><italic>PCGEM1</italic></kwd><kwd><italic>PRNCR1</italic></kwd><kwd><italic>PCAT18</italic></kwd><kwd>Androgen receptor</kwd><kwd>AR regulation</kwd><kwd>Sub-cellular localization</kwd><kwd>Prostate cancer</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>In recent years, long non-coding RNAs (lncRNAs) have emerged as major contributors to cellular homeostasis as well as initiation and progression of numerous diseases [<xref ref-type="bibr" rid="CR1">1</xref>], including prostate cancer (PCa) [<xref ref-type="bibr" rid="CR2">2</xref>]. The latest GENCODE v7 project annotated 14,880 human lncRNA transcripts with only a few characterized to date [<xref ref-type="bibr" rid="CR3">3</xref>]. Of the lncRNAs functionally validated in various human malignancies, a majority have been identified as constituents of oncogenic or tumor suppressive pathways [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>]. Some prominent lncRNAs implicated in prostate carcinogenesis and its progression include prostate cancer associated transcript 1 (<italic>PCAT1</italic>) [<xref ref-type="bibr" rid="CR6">6</xref>], second chromosome locus associated with prostate 1 (<italic>SChLAP1</italic>) [<xref ref-type="bibr" rid="CR7">7</xref>], prostate cancer associated 3 (<italic>PCA3</italic>) [<xref ref-type="bibr" rid="CR8">8</xref>], prostate cancer gene expression marker 1 (<italic>PCGEM1</italic>; aka <italic>PCAT9</italic>) [<xref ref-type="bibr" rid="CR9">9</xref>] and prostate cancer associated non-coding RNA 1 (<italic>PRNCR1</italic>; aka <italic>PCAT8</italic>) [<xref ref-type="bibr" rid="CR10">10</xref>]. Notably, <italic>SChLAP1</italic> has been extensively validated in the clinics as a biomarker of aggressive PCa [<xref ref-type="bibr" rid="CR11">11</xref>] and PCA3 is currently used in diagnostic tests [<xref ref-type="bibr" rid="CR12">12</xref>]. Recently, we described <italic>PCAT18</italic> (aka <italic>Loc728606</italic>, <italic>Linc01092</italic>) as a mediator of metastatic progression based on expression profiling of our patient-derived PCa xenograft models from the Living Tumor Laboratory (LTL) [<xref ref-type="bibr" rid="CR13">13</xref>]. <italic>PCGEM1</italic>, a highly prostate-specific transcript, was one of the first oncogenic lncRNAs to be described in PCa [<xref ref-type="bibr" rid="CR9">9</xref>]. Subsequently, its over-expression was reported to attenuate the apoptotic response [<xref ref-type="bibr" rid="CR14">14</xref>] and also promote cell proliferation and colony formation [<xref ref-type="bibr" rid="CR15">15</xref>]. On the other hand, <italic>PRNCR1</italic> is not as well investigated, although its knockdown reportedly inhibits cell viability [<xref ref-type="bibr" rid="CR10">10</xref>]. Recently, both of these lncRNAs occupied center stage due to their labeling as androgen receptor (AR)-interacting genes [<xref ref-type="bibr" rid="CR16">16</xref>] &#x02013; a claim now disputed [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>AR is a ligand-responsive regulatory protein that mediates the effector functions of androgenic hormones in PCa. It is well established that sustained AR activity is indispensable for PCa cell survival and disease progression, even following androgen-deprivation therapy [<xref ref-type="bibr" rid="CR18">18</xref>-<xref ref-type="bibr" rid="CR20">20</xref>]. This &#x0201c;AR addiction&#x0201d; has led to many studies investigating genes serving as conduits for aberrant restoration of AR activity in recurrent tumors as potential therapeutic targets. In this regard, Srikantan et al. described <italic>PCGEM1</italic> as an AR regulated gene. Later on, <italic>PCGEM1</italic> acting in complicity with <italic>PRNCR1</italic> was shown to physically bind to the AR, thereby facilitating its ligand-independent transcriptional activity in castration resistant PCa (CRPC) [<xref ref-type="bibr" rid="CR16">16</xref>]. In contrast, a recent publication indicated that neither <italic>PCGEM1</italic> nor <italic>PRNCR1</italic> interacted with the AR to render androgen-independence, and that both genes had no prognostic relevance in PCa [<xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, the latter study found no evidence of <italic>PCGEM1</italic> and <italic>PRNCR1</italic> transcripts being AR regulated.</p><p>Notably, all published data on the relationship between AR and <italic>PCGEM1/PRNCR1</italic> hitherto have been derived from <italic>in vitro</italic> experiments, using androgen-sensitive LNCaP cells [<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR17">17</xref>]. There is substantial evidence that transcriptional regulation of genes by a transcription factor is highly dynamic and cellular context-specific [<xref ref-type="bibr" rid="CR21">21</xref>]. In this light, AR was recently demonstrated to induce varied and distinct AR transcriptional programs in patient tumor tissue as opposed to PCa cell lines [<xref ref-type="bibr" rid="CR22">22</xref>]. This puts in doubt the suitability of cell line models for studying the transcriptional activity of the AR. In view of this, we set out to specifically investigate whether <italic>PCGEM1</italic> and <italic>PRNCR1</italic> are relevant in PCa and/or regulated by AR using our LTL patient-derived xenograft PCa models. The LTL has established a large panel of patient-derived PCa xenograft models that, unlike cell lines, retain key biological properties of the original malignancy, including histopathology, genomic profile, cellular heterogeneity, and invasive and metastatic ability [<xref ref-type="bibr" rid="CR23">23</xref>].</p></sec><sec id="Sec2" sec-type="discussion"><title>Findings and discussion</title><p>As a first step, we profiled our two AR+/androgen dependent PCa xenograft models &#x02013; LTL-331 and LTL-313B &#x02013; for expression of both lncRNAs using RNA Sequencing. While <italic>PCGEM1</italic> was considerably expressed (&#x0003e;500 FPKM; fragments per kilobase of exon per million fragments mapped), the expression of <italic>PRNCR1</italic> was &#x0003c;8 FPKM in both models (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). Such scant expression of <italic>PRNCR1</italic> raises serious questions about its biological relevance in AR-dependent PCa. Notably, this negligible expression of <italic>PRNCR1</italic> is in accordance with a more extensive clinical dataset that was recently published [<xref ref-type="bibr" rid="CR17">17</xref>]. Together, these data weaken the claim made by Yang et al. [<xref ref-type="bibr" rid="CR16">16</xref>] that <italic>PRNCR1</italic> plays a vital role in directing the transcriptional activity of AR. We, therefore, focused solely on <italic>PCGEM1</italic> for the remainder of our study.</p><sec id="Sec3"><title>AR regulates expression of <italic>PCGEM1 in vivo</italic></title><p>We performed surgical castration (androgen ablation) of mice bearing the LTL-331 PCa xenograft. Tissue samples were collected just prior to castration and 3&#x000a0;weeks after castration, and were analyzed for gene expression. We observed a significant &#x0003e;500-fold decrease in <italic>PCGEM1</italic> expression post-castration relative to the pre-castration level (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A). Notably, this down-regulation was persistent (&#x0003e;180-fold) even twelve weeks following castration (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S1). In agreement with this data, qPCR analysis on RNA collected before and 12&#x000a0;weeks after castration from a second <italic>in vivo</italic> model, LTL-313B, confirmed the down-regulation of <italic>PCGEM1</italic> (&#x0003e;70-fold; Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>B). In both models, reduced AR activity in response to castration was confirmed by the comparable down-regulation of <italic>PCAT18</italic> (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>A,B), an AR-regulated lncRNA [<xref ref-type="bibr" rid="CR13">13</xref>], and reduction in serum prostate-specific antigen (PSA) levels (at least &#x0003e;45-fold; Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>C). These findings led us to investigate the response of <italic>PCGEM1</italic> to AR stimulation <italic>in vivo</italic>. This was achieved by using intact mouse hosts supplemented with or without pure testosterone at two distinct dosages (1.0&#x000a0;mg and 5.0&#x000a0;mg/mouse) for PCa xenotransplantation of the LTL-331 tumor line. Corresponding to the dosages, serum testosterone levels of 3.96&#x02009;&#x000b1;&#x02009;0.679&#x000a0;ng/ml and 20.6&#x02009;&#x000b1;&#x02009;14.1&#x000a0;ng/ml were achieved in the testosterone supplemented animals versus 1.95&#x02009;&#x000b1;&#x02009;0.106&#x000a0;ng/ml in the intact hosts. Notably, the hosts supplemented with pure testosterone showed a dose-dependent up-regulation of <italic>PCGEM1</italic>, from 5-fold to greater than 22-fold, relative to the hosts without the augmented testosterone (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>D). This coincided with a comparable <italic>PCAT18</italic> up-regulation and serum PSA jump of &#x0003e;2-fold at both dosages.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Expression of</bold>
<bold><italic>PCGEM1</italic></bold>
<bold>in response to AR manipulation</bold>
<bold><italic>in vivo</italic></bold>
<bold>. A</bold>, Expression (qPCR) of the labeled genes in LTL-331 tumor line from intact mice supplemented with testosterone (Test.) (n&#x02009;=&#x02009;3; 5.0&#x000a0;mg/mouse) and 3&#x000a0;weeks after surgical castration (n&#x02009;=&#x02009;4). Expression of all genes is referenced to average expression levels of HPRT1 and GAPDH and is expressed relative to the gene&#x02019;s expression under castrate conditions. ****p&#x02009;&#x0003c;&#x02009;0.0001 (unpaired, 2-tailed <italic>T</italic> test). <bold>B,</bold> Expression of the labeled genes (qPCR) in LTL-313B tumor line pre-castration (n&#x02009;=&#x02009;3) and 12&#x000a0;weeks after castration (n&#x02009;=&#x02009;3). Expression data is referenced and represented as described in the legend of Figure&#x000a0;1A. *p&#x02009;&#x0003c;&#x02009;0.05 (unpaired, 2-tailed <italic>T</italic> test). <bold>C</bold>, Serum PSA levels in corresponding animals bearing LTL-331 or LTL-313B xenograft in A and B, respectively, just prior to castration and at the time of tissue collection after castration. Data is depicted relative to serum PSA values at post-castration time-points. **p&#x02009;&#x0003c;&#x02009;0.01, ***p&#x02009;&#x0003c;&#x02009;0.001 (unpaired, 2-tailed <italic>T</italic> test) <bold>D</bold>, Expression levels (qPCR) of the labeled genes in intact mouse hosts (n&#x02009;=&#x02009;3) or intact hosts supplemented with two distinct dosages of pure testosterone (Test.) (1.0&#x000a0;mg/mouse or 5.0&#x000a0;mg/mouse, n&#x02009;=&#x02009;4 and n&#x02009;=&#x02009;3 respectively). Expression data is referenced as in Figure&#x000a0;1A and is depicted relative to the gene&#x02019;s expression in intact mice. *p&#x02009;&#x0003c;&#x02009;0.05, **p&#x02009;&#x0003c;&#x02009;0.01, ****p&#x02009;&#x0003c;&#x02009;0.0001 (2-Way ANOVA and Tukey&#x02019;s post-test). For all the sub-figures, columns represent mean expression value for the biological replicates (each gene is quantified in triplicates), and bars represent standard deviation. TaqMan assay IDs for all the genes are listed in &#x0201c;Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S4&#x0201d;.</p></caption><graphic xlink:href="12943_2015_314_Fig1_HTML" id="MO1"/></fig></p><p>Notably, previous <italic>in vitro</italic> studies investigating AR-regulation of <italic>PCGEM1</italic> produced conflicting results. Srikantan et al. [<xref ref-type="bibr" rid="CR9">9</xref>] concluded <italic>PCGEM1</italic> is AR-regulated, while Prensner et al. [<xref ref-type="bibr" rid="CR17">17</xref>] found no up-regulation of <italic>PCGEM1</italic> upon AR stimulation. The reason for this discrepancy could lie in the varied experimental conditions employed; in particular, the use of different agonists (viz. dihydrotestosterone (DHT) and synthetic R1881) for AR activation. Although the patterns of DHT-mediated and R1881-mediated gene expression changes are largely parallel, they do not completely overlap [<xref ref-type="bibr" rid="CR24">24</xref>]. Consequently, we repeated this experiment using DHT, a physiological AR ligand, coupled with the sensitive TaqMan qPCR for gene quantification. Two AR+ PCa cell line models that expressed the highest levels of <italic>PCGEM1</italic>, LNCaP and VCaP, were chosen for the <italic>in vitro</italic> studies (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S2). DHT treatment (at 6&#x000a0;h and 12&#x000a0;h) induced a modest (1.8 &#x02013; 2.2-fold) up-regulation of <italic>PCGEM1</italic> in LNCaP cells (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). However, the activation of <italic>PCGEM1</italic> did not continue to escalate in a manner similar to that of canonical AR-regulated genes such as PSA and <italic>PCAT18</italic> over extended time-points (12&#x000a0;h and 24&#x000a0;h). Similar observations were made in VCaP cells upon treatment with DHT (10nM; Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). Most remarkably, the weak AR-activation of <italic>PCGEM1 in vitro</italic> is in accordance with the recent observation that genes actively regulated by the AR in patient tumor tissue show a strong <italic>in vivo</italic> response to castration but a distinctly lesser response to androgen stimulation <italic>in vitro</italic> [<xref ref-type="bibr" rid="CR22">22</xref>]. Notably, also contradicting the original findings [<xref ref-type="bibr" rid="CR9">9</xref>], no significant increase in <italic>PCGEM1</italic> expression was observed <italic>in vitro</italic> (at 6&#x000a0;h, 12&#x000a0;h or 24&#x000a0;h) following stimulation of LNCaP cells with R1881 &#x02013; a synthetic AR ligand (at 10nM; Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C). Similar results were obtained on treatment with a super-physiological concentration of DHT (100nM; Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D). Taken together, our results categorically demonstrate that substantial regulation of <italic>PCGEM1</italic> expression by androgen occurs exclusively <italic>in vivo</italic>.<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Expression of</bold>
<bold><italic>PCGEM1</italic></bold>
<bold>in response to AR activation</bold>
<bold><italic>in vitro</italic></bold>
<bold>.</bold> Expression levels (qPCR) of the labeled genes in <bold>A</bold>, LNCaP cells and <bold>B</bold>, VCaP cells treated with DHT at 10nM for 6&#x000a0;h, 12&#x000a0;h and 24&#x000a0;h. <bold>C</bold>, Expression (qPCR) of the labeled genes in LNCaP cells at 6&#x000a0;h, 12&#x000a0;h and 24&#x000a0;h after treatment with R1881 (10nM) or <bold>D</bold>, with a super-physiological dosage of DHT (100nM). For all the sub-figures, the columns represent mean expression value (2 independent experiments with each gene quantified in triplicates), bars represent standard deviation. NS, not significant; *p&#x02009;&#x0003c;&#x02009;0.05; **p&#x02009;&#x0003c;&#x02009;0.01; ***p&#x02009;&#x0003c;&#x02009;0.001; ****p&#x02009;&#x0003c;&#x02009;0.0001 (unpaired, 2-tailed <italic>T</italic> test).</p></caption><graphic xlink:href="12943_2015_314_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec4"><title>AR activation does not alter the uniform sub-cellular localization of <italic>PCGEM1</italic></title><p>It was previously suggested that a direct AR-<italic>PCGEM1</italic> interaction regulates AR&#x02019;s transcriptional activity [<xref ref-type="bibr" rid="CR16">16</xref>]. In line with this mechanistic model, <italic>PCGEM1</italic>&#x02019;s suspected function as a transcriptional co-regulator would imply it to be predominantly contained in the nucleus, in particular when the AR is transcriptionally active. However, sub-cellular localization of <italic>PCGEM1</italic> had never been investigated. Addressing this issue, we performed cellular fractionation of PCa patient-derived xenograft cells to isolate the nuclear and cytoplasmic RNA fractions, and quantified gene expression.</p><p>Our data shows that <italic>PCGEM1</italic> is evenly distributed between the nucleus and the cytoplasm of LTL-331 cells harvested from intact mouse hosts or intact hosts supplemented with testosterone (Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A,B). Expected cytoplasmic localization of GAPDH and Actin (&#x0003e;85% for both) and nuclear localization of small nucleolar RNA 55 (<italic>snoRNA55</italic>) and <italic>MALAT1</italic> (&#x0003e;80% for both) authenticate our findings. A similar sub-cellular distribution of <italic>PCGEM1</italic> was observed in DHT treated and untreated LNCaP cells as well (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S3A, B). While these results do not conclusively rule out the possibility that <italic>PCGEM1</italic> may be interacting with the AR, they demonstrate for the first time that <italic>PCGEM1</italic> is not selectively localized in the nucleus; or is shuttled to it upon transcriptional activation of the AR. These findings also highlight the gap in our understanding of lncRNAs with proposed cell compartment-specific functions. The unresolved question is whether lncRNAs with nuclear roles are contained in the nucleus throughout their lifetime, or do they also shuttle to the cytoplasm where they can adopt additional roles? For instance, <italic>H19</italic>, one of the most well characterized lncRNAs, is associated with both nuclear and cytoplasmic functions i.e. chromatin modulation [<xref ref-type="bibr" rid="CR25">25</xref>] and micro-RNA generation [<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref>], respectively. Collectively, our results warrant further verification of the alleged function of <italic>PCGEM1</italic> as a transcriptional co-regulator of the AR, in addition to investigating its potential role in the cytoplasm. For detailed information about all the experiments refer to &#x0201c;Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Supplementary methods and materials.&#x0201d;<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Subcellular localization of</bold>
<bold><italic>PCGEM1</italic></bold>
<bold>with or without AR activation</bold>
<bold><italic>in vivo</italic></bold>
<bold>.</bold> Sub-cellular localization of <italic>PCGEM1</italic>, GAPDH mRNA, Actin mRNA, <italic>snoRNA55</italic> and <italic>MALAT1</italic> in <bold>A</bold>, LTL-331 cells harvested from intact mouse hosts (n&#x02009;=&#x02009;2) and <bold>B</bold>, intact hosts supplemented with pure testosterone (Test. Suppl; 5.0&#x000a0;mg/mouse, n&#x02009;=&#x02009;2). For each gene, expression in nuclear and cytoplasmic fractions is represented as a percentage of the total expression. The dashed line indicates the 50% distribution mark. The columns represent mean % distribution value for the biological replicates (each gene is quantified in triplicates), and the bars represent standard deviation.</p></caption><graphic xlink:href="12943_2015_314_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec5"><title><italic>PCGEM1</italic> is implicated in early stages of PCa</title><p>Our results to this point indicate <italic>PCGEM1</italic> to be an <italic>in vivo</italic> androgen regulated gene, with uniform distribution in PCa cell nucleus and cytoplasm. One remaining question, however, is the stage of PCa in which <italic>PCGEM1</italic> might be biologically most relevant. To this end we investigated a patient database consisting of microarray and clinical data on 131 primary PCa, 19 metastasized PCa and 29 normal prostatic tissue samples [<xref ref-type="bibr" rid="CR28">28</xref>]. Here we observed that <italic>PCGEM1</italic> was significantly up-regulated only in primary PCa but not in metastasized PCa relative to normal prostate tissue. In fact, <italic>PCGEM1</italic> expression was significantly down-regulated in metastasized tumors relative to primary tumors (Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Figure S4). Adding to a recent study discrediting the involvement of <italic>PCGEM1</italic> in progression of localized PCa to CRPC [<xref ref-type="bibr" rid="CR17">17</xref>], our analysis further raises the question of the biological relevance of <italic>PCGEM1</italic> in survival and proliferation of metastasized PCa cells themselves. In view of this, <italic>PCGEM1</italic> is most likely implicated only in the early stages of the disease warranting further experimental validation. To explore this further, we performed Pearson&#x02019;s Correlation analysis to identify genes that are positively associated with <italic>PCGEM1</italic> expression, hereafter referred to as <italic>PCGEM1</italic>-associated gene expression signature (PES) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2), and uploaded the list into the Oncomine database. As previously demonstrated for <italic>PCGEM1</italic>, the PES was also significantly up-regulated in PCa relative to other neoplasms and in PCa versus normal prostate tissue (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Corroborating the relevance of <italic>PCGEM1</italic> in early stages of PCa, PES was consistently repressed in metastatic and high Gleason PCa relative to primary and low Gleason neoplasms, respectively (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Notably, this trend was observed in several independent patient cohorts totaling more than 1100 samples. Accordingly, the PES was significantly repressed in patients exhibiting poor clinical outcomes.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold><italic>PCGEM1</italic></bold>
<bold>-associated expression signature in PCa patient samples</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Concept</bold>
</th><th>
<bold>Studies (Up/Down)</bold>
</th><th>
<bold>P-value</bold>
</th><th>
<bold>Odds ratio</bold>
</th><th>
<bold>Total samples</bold>
</th></tr></thead><tbody><tr valign="top"><td>PCa vs. Other Neoplasms</td><td>1/0</td><td>4.44E-15</td><td>30.9</td><td>1468</td></tr><tr valign="top"><td>PCa vs. Normal Prostate</td><td>5/0</td><td>1.88E-10 - 2.00E-03</td><td>14.5 - 4.5</td><td>299</td></tr><tr valign="top"><td>Metastatic PCa vs. Primary PCa</td><td>0/6</td><td>6.69E-13 - 5.00E-03</td><td>27.0 - 4.5</td><td>448</td></tr><tr valign="top"><td>High Gleason PCa vs. Low Gleason PCa</td><td>0/5</td><td>8.01E-11 - 6.00E-3</td><td>16.8 - 5.0</td><td>676</td></tr><tr valign="top"><td>Hormone-Refractory PCa vs. Hormone-na&#x000ef;ve PCa</td><td>0/1</td><td>4.74E-05</td><td>9.6</td><td>20</td></tr><tr valign="top"><td>Clinical Outcomes</td><td/><td/><td/><td/></tr><tr valign="top"><td>Reoccurrence at 3 or 5&#x000a0;years</td><td>0/2</td><td>1.45E-06 - 4.52E-04</td><td>8.4 - 5.1</td><td>168</td></tr><tr valign="top"><td>Dead at 3 or 5&#x000a0;years</td><td>0/2</td><td>4.65E-07 - 9.02E-04</td><td>20.6 -7.8</td><td>721</td></tr></tbody></table><table-wrap-foot><p>The MSKCC database was queried using cBioPortal for genes that are co-expressed with <italic>PCGEM1</italic> (Pearson&#x02019;s Correlation&#x02009;&#x0003e;&#x02009;0.50), which were then uploaded into the Oncomine database (thresholds: p-value&#x02009;&#x0003c;&#x02009;0.01, odds ratio&#x02009;&#x0003e;&#x02009;2). Only clinically-related Oncomine concepts were analyzed and are listed in the first column. Here, <italic>PCGEM1</italic> expression in PCa was compared to 15 other neoplasms. The second column summarizes the total number of independent studies showing either up- or down-regulation of PES for the corresponding concept. &#x0201c;Total Samples&#x0201d; reflect the grand total of number of patients in every study that met the threshold for the corresponding concept. Oncomine (Compendia Bioscience) was used for statistical analysis.</p></table-wrap-foot></table-wrap></p><p>A review of literature also reveals that <italic>PCGEM1</italic> is up-regulated in normal prostate epithelial cells of men with a family history of PCa [<xref ref-type="bibr" rid="CR15">15</xref>] and certain single-nucleotide polymorphisms in the <italic>PCGEM1</italic> gene are associated with a higher risk of PCa development in Chinese men [<xref ref-type="bibr" rid="CR29">29</xref>]. Together, these findings support the testable hypothesis that <italic>PCGEM1</italic> is more important in the early stages, possibly initiation, of primary PCa. Interestingly, the <italic>PCGEM1</italic> signature was also under-expressed in hormone-refractory PCa relative to hormone-na&#x000ef;ve PCa (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>); and the pathway analysis revealed PES to be most significantly down-regulated (p&#x02009;=&#x02009;5.47E-14, odds ratio&#x02009;=&#x02009;121.4) in patients receiving androgen-deprivation therapy (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S3) lending further support to <italic>in vivo</italic> AR-regulation of <italic>PCGEM1</italic>.</p><p>Our work brings in light an even more pertinent concern with exploring AR transcriptional activity using cell line models. Recently, cell line models in accordance with their metastatic origin were demonstrated to exhibit the AR regulatory program that is active in metastatic advanced PCa as opposed to primary PCa [<xref ref-type="bibr" rid="CR22">22</xref>]. The AR regulatory activity in cultured cell line models (including LNCaP) had a greater overlap to CRPC (31% overlap) than untreated primary PCa (merely 3% overlap) (see [<xref ref-type="bibr" rid="CR22">22</xref>]). Besides the absent cell microenvironment, this describes further limitations of cell line models for investigating AR-regulation, in particular for genes with a clinical expression profile akin to that of <italic>PCGEM1</italic>. Simultaneously, it underscores the importance of using clinically relevant models that best represent the original malignancy. With mounting evidence for lncRNAs implicated in carcinogenesis and cancer progression, we regard lncRNAs as essential in decrypting cancer cell biology. Our study corroborates the irrelevance of <italic>PRNCR1</italic> in PCa, and confirms <italic>PCGEM1</italic> as an <italic>in vivo</italic> AR-regulated transcript as well as rationalizes its oncogenic involvement in early stages of the disease.</p></sec></sec></body><back><app-group><app id="App1"><sec id="Sec6"><title>Additional files</title><p><media position="anchor" xlink:href="12943_2015_314_MOESM1_ESM.docx" id="MOESM1"><label>Additional file 1: Table S1.</label><caption><p>RNA-Sequencing data for <italic>PCGEM1</italic> and <italic>PRNCR1</italic> in LTL xenograft models. Transcript name, ensembl ID, transcript class, chromosomal coordinates and FPKM values in LTL-331 and LTL-313B for GAPDH (control), <italic>PCGEM1</italic> and <italic>PRNCR1</italic>. <bold>Table S2.</bold>
<italic>PCGEM1</italic>-associated expression signature (PES) in PCa Samples. <italic>PCGEM1</italic> was queried using cBioPortal in the prostate adenocarcinoma (MSKCC, Cancer Cell 2010) cancer study for mRNA expression data. List of genes with the highest expression correlation with <italic>PCGEM1</italic> (pearson&#x02019;s correlation&#x02009;&#x0003e;&#x02009;0.50) was obtained from the &#x0201c;Co-Expression&#x0201d; module on cBioPortal. A total of 29 genes, listed in the first column, were significantly co-expressed with <italic>PCGEM1</italic>. Second and third columns list the Pearson&#x02019;s and Spearman&#x02019;s correlation values that were obtained from the cBioPortal analysis. <bold>Table S3.</bold> Literature-defined concepts associated with PES. All transcripts that positively associated with <italic>PCGEM1</italic> (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2) were uploaded into the Oncomine database and analyzed for &#x0201c;literature-defined concepts&#x0201d; (thresholds: P-value&#x02009;&#x0003c;&#x02009;0.01. odds ratio&#x02009;&#x0003e;&#x02009;2). Here, we show only the top 5 solid tumor-related concepts significantly associated with PES. <bold>Table S4.</bold> Gene expression TaqMan assays. All assays were purchased from Life Technologies and were pre-designed for the probe to span exons except for <italic>snoRNA55</italic>, for which both the primers and probe map within a single exon. All probes had the FAM reporter signal.</p></caption></media><media position="anchor" xlink:href="12943_2015_314_MOESM2_ESM.docx" id="MOESM2"><label>Additional file 2: Figure S1.</label><caption><p>Expression of <italic>PCGEM1</italic> in LTL-331 castration time series. A, Expression (qPCR) of the labeled genes in LTL-331 tumor line from mice supplemented with testosterone (Test.) (n = 3, 5.0 mg/mouse), or after surgical castration (n = 1, at 1, 2, 3, 8 and 12 weeks). Expression of all genes is referenced to average expression levels of HPRT1 and GAPDH and is expressed relative to the gene&#x02019;s expression in testosterone-supplemented mice. Dots represent mean expression value and bars represent standard deviation. B, Serum PSA levels from the corresponding LTL-331 xenograft bearing animals in A. <bold>Figure S2.</bold>
<italic>PCGEM1</italic> basal expression profile in a panel of PCa cell lines. Expression levels of <italic>PCGEM1</italic> in a non-neoplastic prostate cell line and a panel of commonly used AR+ and AR- PCa cell line models. <italic>PCGEM1</italic> expression is referenced to average expression levels of HPRT1 and GAPDH and is expressed relative to its expression in 22RV1 cells where it is barely expressed (Ct value = ~41). No column represents that <italic>PCGEM1</italic> transcript was undetectable in the corresponding cell line using the Ct cutoff of 45 cycles. Columns represent mean expression value and bars represent standard deviation. <bold>Figure S3.</bold> Sub-cellular localization of <italic>PCGEM1</italic> with or without DHT treatment <italic>in vitro. E</italic>xpression of the labelled genes (qPCR) in sub-cellular fractions of A, untreated LNCaP cells and B, LNCaP cells stimulated with DHT (10nM) for 12 h. Columns represent mean distribution value from 2 independent experiments and bars represent standard deviation. <bold>Figure S4.</bold> Taylor PCa cohort analysis. <italic>PCGEM1</italic> expression (microarray data) in 131 primary PCa, 19 partially paired secondary metastatic PCa tissues and 29 normal prostatic tissues. These are median-centered values where bars represent maximum and minimum value per group. NS, not significant; ***p &#x0003c; 0.001 (2-Way ANOVA and Tukey&#x02019;s post-test).</p></caption></media><media position="anchor" xlink:href="12943_2015_314_MOESM3_ESM.docx" id="MOESM3"><label>Additional file 3:</label><caption><p>
<bold>Supplementary methods and materials.</bold>
</p></caption></media></p></sec></app></app-group><fn-group><fn><p>Yuzhuo Wang and Cheryl D Helgason contributed equally to this work.</p></fn><fn><p><bold>Competing interests</bold></p><p>All authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>AP and FC conceived and designed the study with guidance from YZW and CDH. AP and FC performed the cBioPortal and Oncomine analysis. AP performed the <italic>in vitro</italic> experiments, RNA extractions and gene quantifications, analyzed and interpreted data, and wrote the entire manuscript and prepared the figures. HX and YW did the <italic>in vivo</italic> experiments. FM, VRR and CC performed genomic analysis. HHL, DL, NRNS and HC helped in sample preparation. PLC critically revised the paper. YZW and CDH participated in designing experiments and critically revised the paper as well. In addition, all authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was financially supported by Canadian Cancer Society Research Institute, grant number: 701097 (CDH); Canadian Institutes of Health Research, grant numbers: 102604&#x02013;1, 119991&#x02013;1, 123449&#x02013;1 (YZW); Prostate Cancer Canada (YZW); Terry Fox Research Institute, grant number: 116129&#x02013;1 (YZW); Michael Smith Foundation for Health Research Fellowship, number: 5629 (FC); and BC Prostate Cancer Foundation &#x0201c;grant-in-aid&#x0201d; award (FC).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wapinski</surname><given-names>O</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Long noncoding RNAs and human disease</article-title><source>Trends Cell Biol</source><year>2011</year><volume>21</volume><issue>6</issue><fpage>354</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2011.04.001</pub-id><pub-id pub-id-type="pmid">21550244</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>AL</given-names></name><name><surname>Tuzova</surname><given-names>AV</given-names></name><name><surname>Bolton</surname><given-names>EM</given-names></name><name><surname>Lynch</surname><given-names>TH</given-names></name><name><surname>Perry</surname><given-names>AS</given-names></name></person-group><article-title>Long noncoding RNAs and prostate carcinogenesis: the missing &#x02018;linc&#x02019;?</article-title><source>Trends Mol Med</source><year>2014</year><volume>20</volume><issue>8</issue><fpage>428</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2014.03.005</pub-id><pub-id pub-id-type="pmid">24836411</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derrien</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Bussotti</surname><given-names>G</given-names></name><name><surname>Tanzer</surname><given-names>A</given-names></name><name><surname>Djebali</surname><given-names>S</given-names></name><name><surname>Tilgner</surname><given-names>H</given-names></name><etal/></person-group><article-title>The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression</article-title><source>Genome Res</source><year>2012</year><volume>22</volume><issue>9</issue><fpage>1775</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1101/gr.132159.111</pub-id><pub-id pub-id-type="pmid">22955988</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Clermont</surname><given-names>PL</given-names></name><name><surname>Parolia</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Helgason</surname><given-names>CD</given-names></name></person-group><article-title>The non-coding transcriptome as a dynamic regulator of cancer metastasis</article-title><source>Cancer Metastasis Rev</source><year>2013</year><volume>33</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s10555-013-9455-3</pub-id><pub-id pub-id-type="pmid">24346158</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><article-title>The emergence of lncRNAs in cancer biology</article-title><source>Cancer Discov</source><year>2011</year><volume>1</volume><issue>5</issue><fpage>391</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-11-0209</pub-id><pub-id pub-id-type="pmid">22096659</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Iyer</surname><given-names>MK</given-names></name><name><surname>Balbin</surname><given-names>OA</given-names></name><name><surname>Dhanasekaran</surname><given-names>SM</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Brenner</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression</article-title><source>Nat Biotechnol</source><year>2011</year><volume>29</volume><issue>8</issue><fpage>742</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nbt.1914</pub-id><pub-id pub-id-type="pmid">21804560</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Iyer</surname><given-names>MK</given-names></name><name><surname>Sahu</surname><given-names>A</given-names></name><name><surname>Asangani</surname><given-names>IA</given-names></name><name><surname>Cao</surname><given-names>Q</given-names></name><name><surname>Patel</surname><given-names>L</given-names></name><etal/></person-group><article-title>The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex</article-title><source>Nat Genet</source><year>2013</year><volume>45</volume><fpage>1392</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/ng.2771</pub-id><pub-id pub-id-type="pmid">24076601</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bussemakers</surname><given-names>MJ</given-names></name><name><surname>van Bokhoven</surname><given-names>A</given-names></name><name><surname>Verhaegh</surname><given-names>GW</given-names></name><name><surname>Smit</surname><given-names>FP</given-names></name><name><surname>Karthaus</surname><given-names>HF</given-names></name><name><surname>Schalken</surname><given-names>JA</given-names></name><etal/></person-group><article-title>DD3: a new prostate-specific gene, highly over expressed in prostate cancer</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><issue>23</issue><fpage>5975</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10606244</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srikantan</surname><given-names>V</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Petrovics</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Augustus</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>L</given-names></name><etal/></person-group><article-title>PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>2000</year><volume>97</volume><issue>22</issue><fpage>12216</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.22.12216</pub-id><pub-id pub-id-type="pmid">11050243</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>S</given-names></name><name><surname>Nakagawa</surname><given-names>H</given-names></name><name><surname>Uemura</surname><given-names>M</given-names></name><name><surname>Piao</surname><given-names>L</given-names></name><name><surname>Ashikawa</surname><given-names>K</given-names></name><name><surname>Hosono</surname><given-names>N</given-names></name><etal/></person-group><article-title>Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility</article-title><source>Cancer Sci</source><year>2011</year><volume>102</volume><issue>1</issue><fpage>245</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01737.x</pub-id><pub-id pub-id-type="pmid">20874843</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehra</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Udager</surname><given-names>AM</given-names></name><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Sahu</surname><given-names>A</given-names></name><name><surname>Iyer</surname><given-names>MK</given-names></name><etal/></person-group><article-title>A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer</article-title><source>Neoplasia</source><year>2014</year><volume>16</volume><issue>12</issue><fpage>1121</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2014.11.006</pub-id><pub-id pub-id-type="pmid">25499224</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roobol</surname><given-names>MJ</given-names></name><name><surname>Schroder</surname><given-names>FH</given-names></name><name><surname>van Leeuwen</surname><given-names>P</given-names></name><name><surname>Wolters</surname><given-names>T</given-names></name><name><surname>van den Bergh</surname><given-names>RC</given-names></name><name><surname>van Leenders</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test</article-title><source>Eur Urol</source><year>2010</year><volume>58</volume><fpage>475</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2010.06.039</pub-id><pub-id pub-id-type="pmid">20637539</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Watahiki</surname><given-names>A</given-names></name><name><surname>Quagliata</surname><given-names>L</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Pikor</surname><given-names>L</given-names></name><name><surname>Parolia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><issue>3</issue><fpage>764</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">24519926</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Ravindranath</surname><given-names>L</given-names></name><name><surname>Tran</surname><given-names>N</given-names></name><name><surname>Petrovics</surname><given-names>G</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name></person-group><article-title>Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1</article-title><source>DNA Cell Biol</source><year>2006</year><volume>25</volume><issue>3</issue><fpage>135</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1089/dna.2006.25.135</pub-id><pub-id pub-id-type="pmid">16569192</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrovics</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Makarem</surname><given-names>M</given-names></name><name><surname>Street</surname><given-names>JP</given-names></name><name><surname>Connelly</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><etal/></person-group><article-title>Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><issue>2</issue><fpage>605</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1207069</pub-id><pub-id pub-id-type="pmid">14724589</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Tanasa</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><etal/></person-group><article-title>LncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs</article-title><source>Nature</source><year>2013</year><volume>500</volume><issue>7464</issue><fpage>598</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/nature12451</pub-id><pub-id pub-id-type="pmid">23945587</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prensner</surname><given-names>JR</given-names></name><name><surname>Sahu</surname><given-names>A</given-names></name><name><surname>Iyer</surname><given-names>MK</given-names></name><name><surname>Malik</surname><given-names>R</given-names></name><name><surname>Chandler</surname><given-names>B</given-names></name><name><surname>Asangani</surname><given-names>IA</given-names></name><etal/></person-group><article-title>The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><issue>6</issue><fpage>1434</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">24727738</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balk</surname><given-names>SP</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name></person-group><article-title>AR, the cell cycle, and prostate cancer</article-title><source>Nucl Recept Signal</source><year>2008</year><volume>6</volume><fpage>e001</fpage><pub-id pub-id-type="pmid">18301781</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifi</surname><given-names>N</given-names></name><name><surname>Gulley</surname><given-names>JL</given-names></name><name><surname>Dahut</surname><given-names>WL</given-names></name></person-group><article-title>Androgen deprivation therapy for prostate cancer</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>2</issue><fpage>238</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1001/jama.294.2.238</pub-id><pub-id pub-id-type="pmid">16014598</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>IG</given-names></name></person-group><article-title>Maintaining and reprogramming genomic androgen receptor activity in prostate cancer</article-title><source>Nat Rev Cancer</source><year>2014</year><volume>14</volume><issue>3</issue><fpage>187</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1038/nrc3678</pub-id><pub-id pub-id-type="pmid">24561445</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fry</surname><given-names>CJ</given-names></name><name><surname>Farnham</surname><given-names>PJ</given-names></name></person-group><article-title>Context-dependent transcriptional regulation</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><issue>42</issue><fpage>29583</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.42.29583</pub-id><pub-id pub-id-type="pmid">10514422</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>NL</given-names></name><name><surname>Massie</surname><given-names>CE</given-names></name><name><surname>Ramos-Montoya</surname><given-names>A</given-names></name><name><surname>Zecchini</surname><given-names>V</given-names></name><name><surname>Scott</surname><given-names>HE</given-names></name><name><surname>Lamb</surname><given-names>AD</given-names></name><etal/></person-group><article-title>The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man</article-title><source>Cancer Cell</source><year>2013</year><volume>23</volume><issue>1</issue><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.11.010</pub-id><pub-id pub-id-type="pmid">23260764</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>D</given-names></name><name><surname>Wyatt</surname><given-names>AW</given-names></name><name><surname>Xue</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Haegert</surname><given-names>A</given-names></name><etal/></person-group><article-title>High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><issue>4</issue><fpage>1272</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2921-T</pub-id><pub-id pub-id-type="pmid">24356420</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DePrimo</surname><given-names>SE</given-names></name><name><surname>Diehn</surname><given-names>M</given-names></name><name><surname>Nelson</surname><given-names>JB</given-names></name><name><surname>Reiter</surname><given-names>RE</given-names></name><name><surname>Matese</surname><given-names>J</given-names></name><name><surname>Fero</surname><given-names>M</given-names></name><etal/></person-group><article-title>Transcriptional programs activated by exposure of human prostate cancer cells to androgen</article-title><source>Genome Biol</source><year>2002</year><volume>3</volume><issue>7</issue><fpage>RESEARCH0032</fpage><pub-id pub-id-type="doi">10.1186/gb-2002-3-7-research0032</pub-id><pub-id pub-id-type="pmid">12184806</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name></person-group><article-title>Long non-coding RNA H19 increases bladder cancer metastasis by associating with EZH2 and inhibiting E-cadherin expression</article-title><source>Cancer Lett</source><year>2013</year><volume>333</volume><issue>2</issue><fpage>213</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.01.033</pub-id><pub-id pub-id-type="pmid">23354591</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>X</given-names></name><name><surname>Cullen</surname><given-names>BR</given-names></name></person-group><article-title>The imprinted H19 noncoding RNA is a primary microRNA precursor</article-title><source>RNA</source><year>2007</year><volume>13</volume><issue>3</issue><fpage>313</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1261/rna.351707</pub-id><pub-id pub-id-type="pmid">17237358</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>WP</given-names></name><name><surname>Ng</surname><given-names>EK</given-names></name><name><surname>Ng</surname><given-names>SS</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Sung</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer</article-title><source>Carcinogenesis</source><year>2010</year><volume>31</volume><issue>3</issue><fpage>350</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgp181</pub-id><pub-id pub-id-type="pmid">19926638</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Hieronymus</surname><given-names>H</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Carver</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Integrative genomic profiling of human prostate cancer</article-title><source>Cancer Cell</source><year>2010</year><volume>18</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.05.026</pub-id><pub-id pub-id-type="pmid">20579941</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Chu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association between lncrna PCGEM1 polymorphisms and prostate cancer risk</article-title><source>Prostate Cancer Prostatic Dis</source><year>2013</year><volume>16</volume><issue>2</issue><fpage>139</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">23459097</pub-id></element-citation></ref></ref-list></back></article>